Gene Expression, Non-Coding RNA, and Circular RNA Alterations in Patients with T-Prolymphocytic Leukemia

Area of Science:

• Genomics and Molecular Biology
• Oncology
• Transcriptomics

Background:

• T-cell prolymphocytic leukemia (T-PLL) is a rare T-cell malignancy with poor prognosis.
• Understanding molecular drivers and disease heterogeneity is crucial for developing new therapies.
• Non-coding RNAs play a significant role in cancer development and progression.

Purpose of the Study:

• To identify molecular liabilities and understand disease heterogeneity in T-cell prolymphocytic leukemia (T-PLL).
• To profile gene expression and pathway alterations in malignant T-PLL cells.
• To investigate genotype-phenotype relationships and identify potential therapeutic targets.

Main Methods:

• RNA-sequencing (RNA-seq) profiling of T-PLL samples and normal T-cells.
• Analysis of gene expression, pathway alterations, and non-coding RNA expression (lncRNAs, circRNAs).
• Genotype-phenotype association analysis focusing on recurrent oncogenic variants.

Main Results:

• Profound alterations in non-coding, antisense, and circular RNA expression were observed in T-PLL.
• Activation of oncogenic pathways (PI3K/AKT/mTOR, Wnt) and suppression of normal T-cell functions were identified.
• Specific lncRNAs (e.g., NEAT1, MIAT, LUCAT1, FIRRE, TERC, XIST, PVT1) and circRNAs (e.g., circSEMA4B, circSATB1, circFIRRE, circPVT1, circFKBP5) were differentially expressed.
• Potential links between driver variants (STAT5B, JAK3, ATM, KMT2C, ARID1A) and gene/circRNA expression changes were suggested.

Conclusions:

• Transcriptomic profiling and genotype-phenotype analysis revealed specific molecular signatures in T-PLL.
• Identified genes, non-coding RNAs, and pathways represent potential therapeutic targets.
• Further investigation is warranted for developing novel treatment strategies for T-PLL.